Bristol-Myers Squibb (BMS) has been a center of news in the biotech industry recently. Their advertisement for
Cobenfy has been targeted by the FDA. Furthermore, BMS has offered their
blood thinner Eliquis free to Medicaid in the U.S. as part of a pricing deal. Recent FDA approval of
Cytokinetics’ heart drug presents a new rivalry for BMS. In the midst of these developments, BMS also faces a
$6.7 billion lawsuit over a delayed cancer drug as ruled by a US judge. Despite these confrontations, the company remains in active
partnerships such as the one with
Harbour BioMed for the discovery and development of multi-specific antibodies, a deal worth up to $1.1B. BMS shares have been the topic of investment debates, while the company CEO,
Chris Boerner, believes his ‘patent cliff’ plan was missing company culture. BMS’s
Breyanzi approval by the U.S. FDA sets it apart as the first and only CAR T Cell Therapy for adults with relapsed or refractory Marginal Zone Lymphoma (MZL). BMS has also committed to environmental sustainability and making strides in cancer care through partnerships.
Bristol-Myers Squibb News Analytics from Wed, 14 May 2025 07:00:00 GMT to Sat, 20 Dec 2025 13:59:00 GMT -
Rating 3
- Innovation 4
- Information 8
- Rumor -2
